Tirzepatide In Community Settings

From 23 June, some people living with obesity may be eligible to access Tirzepatide (Mounjaro®) for weight loss purposes in community settings as outlined in NICE guidelines. Access is prioritised for those with the greatest clinical need (see page 7 of the interim commissioning guidance for eligibility criteria).

Although many patients living with obesity may meet the product license criteria for Tirzepatide (BMI >30, or >27.5 with one or more comorbidities), please be aware that only patients in Cohort 1 (defined as having a BMI >40 and four or more comorbidities – see page 11 of the NICE guidance for full criteria) are currently eligible for access.

At present, there is no commissioned pathway for managing Cohort 1 patients in South Yorkshire. However, South Yorkshire Integrated Care Board (ICB) and local Places are working to develop appropriate services, which will include wraparound care.

To support you in responding to patient enquiries, an FAQ document has been produced and is available here